StreetInsider.com News Articles

Leerink Starts Phathom Pharmaceuticals (PHAT) at Market Perform

Wed, 09 Sep 2026 06:11:09 -0400

Leerink analyst Daniel Clark initiates coverage on Phathom Pharmaceuticals (NASDAQ: PHAT) with a Market Perform rating and a price target of $10.00.

For an analyst ratings summary and ratings history on Phathom Pharmaceuticals click here. For more ratings news on Phathom Pharmaceuticals click here.

Shares of Phathom Pharmaceuticals closed at $9.43 yesterday.

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

Tue, 01 Sep 2026 08:00:00 -0400

FLORHAM PARK, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following upcoming investor conferences in September:

2026 Cantor Global Healthcare Conference in New York, NY
Date: Wednesday, September 9, 2026
Fireside Chat: 10:55 am EDT
Management to participate in one-on-one meetings throughout the conference

H.C. Wainwright 28th Annual Global Investment Conference in New York, NY
Date: Tuesday, September 15, 2026
Fireside Chat: 3:30 pm

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

Tue, 01 Sep 2026 08:00:00 -0400

H.C. Wainwright 28th Annual Global Investment Conference in New York, NY
Date: Tuesday, September 15, 2026
Fireside Chat: 3:30 pm

Phathom Pharmaceuticals (PHAT) PT Lowered to $14 at Barclays

Mon, 17 Aug 2026 04:53:17 -0400

Barclays analyst Glen Santangelo lowered the price target on Phathom Pharmaceuticals (NASDAQ: PHAT) to $14.00 (from $18.00) while maintaining a Overweight rating.

H.C. Wainwright Reiterates Buy Rating on Phathom Pharmaceuticals (PHAT)

Fri, 31 Jul 2026 06:47:30 -0400

H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating and $26.00 price target on Phathom Pharmaceuticals (NASDAQ: PHAT).

The analyst commented: "We believe the company delivered for the quarter based on: (1) record 2Q26 revenue reflecting 88% growth YoY from 2Q25, and 27% over the prior quarter, discussed below; (2) operating profitability excluding stock-based compensation for the quarter; (3) announced new plans to initiate a registrational Phase 3 program for vonoprazan in the as-needed on-demand treatment on non-erosive GERD (NERD) patients, notably where traditional PPI therapies lack approval and the necessary efficacy profile; (4) completed enrollment for the Phase 2 pHalcon-EoE-201

Phathom Pharmaceuticals (PHAT) PT Lowered to $22 at Guggenheim

Thu, 30 Jul 2026 13:04:27 -0400

(Updated - July 30, 2026 1:04 PM EDT)

Guggehneim analyst Yatin Suneja lowered the price target on Phathom Pharmaceuticals (NASDAQ: PHAT) to $22.00 (from $25.00) while maintaining a Buy rating.

The analyst commented: "PHAT has delivered robust Q/Q Voquezna TRx and revenue growth, exceeding consensus expectations, as well as achieving operational profitability for the first time in the company's history. Despite this momentum, mgmt has lowered FY26 revenue guidance marginally to $310-325MM (From $320-345MM), citinglogistical issues with prescribing and prior authorization process which requires a bit more education. While there is no coverage or demand issue, mgmt noted some emergence of increased

Phathom Pharmaceuticals (PHAT) PT Lowered to $22 at Guggenheim

Thu, 30 Jul 2026 13:04:27 -0400

(Updated - July 30, 2026 1:04 PM EDT)

Guggehneim analyst Yatin Suneja lowered the price target on Phathom Pharmaceuticals (NASDAQ: PHAT) to $22.00 (from $25.00) while maintaining a Buy rating.

Phathom Pharmaceuticals, Inc. (PHAT) Tops Q2 EPS by 19c

Thu, 30 Jul 2026 07:36:26 -0400

Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) reported Q2 EPS of $0.00, $0.19 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $74.27 million versus the consensus estimate of $73.98 million.

For earnings history and earnings-related data on Phathom Pharmaceuticals, Inc. (PHAT) click here.

Form 10-Q Phathom Pharmaceuticals, For: Jun 30

Thu, 30 Jul 2026 07:06:00 -0400

si-local-file:///var/storage/secattach/20260730/26838543.html

Form 10-Q Phathom Pharmaceuticals, For: Jun 30

Thu, 30 Jul 2026 07:06:00 -0400

si-local-file:///var/storage/secattach/20260730/26838543.html

Form 8-K Phathom Pharmaceuticals, For: Jul 30

Thu, 30 Jul 2026 07:05:00 -0400

si-local-file:///var/storage/secattach/20260730/26838528.html

Form 8-K Phathom Pharmaceuticals, For: Jul 30

Thu, 30 Jul 2026 07:05:00 -0400

si-local-file:///var/storage/secattach/20260730/26838528.html

Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 30 Jul 2026 06:59:00 -0400

~1.7 million total VOQUEZNA^® prescriptions filled to date
Record Q2 2026 net revenues of $74.3 million, increased 88% vs. Q2 2025 and 27% vs. Q1 2026
Q2 operating expenses of $63.1 million, reduced by 33% vs. Q2 2025
Initiating Phase 3 clinical trial evaluating as-needed dosing of VOQUEZNA^® in patients with Non-Erosive GERD (NERD)
Updated full-year 2026 financial guidance
Conference call and webcast today, July 30, 2026, at 8:00 a.m. EDT

FLORHAM PARK, N.J., July 30, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for

Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 30 Jul 2026 06:59:00 -0400

~1.7 million total VOQUEZNA^® prescriptions filled to date
Record Q2 2026 net revenues of $74.3 million, increased 88% vs. Q2 2025 and 27% vs. Q1 2026
Q2 operating expenses of $63.1 million, reduced by 33% vs. Q2 2025
Initiating Phase 3 clinical trial evaluating as-needed dosing of VOQUEZNA^® in patients with Non-Erosive GERD (NERD)
Updated full-year 2026 financial guidance
Conference call and webcast today, July 30, 2026, at 8:00 a.m. EDT

FLORHAM PARK, N.J., July 30, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for

Form SCHEDULE 13G Phathom Pharmaceuticals, Filed by: BlackRock, Inc.

Wed, 29 Jul 2026 15:21:00 -0400

si-local-file:///var/storage/secattach/20260729/26834313.html

Form SCHEDULE 13G Phathom Pharmaceuticals, Filed by: BlackRock, Inc.

Wed, 29 Jul 2026 15:21:00 -0400

si-local-file:///var/storage/secattach/20260729/26834313.html

Form SCHEDULE 13G/A Phathom Pharmaceuticals, Filed by: MILLENNIUM MANAGEMENT LLC

Mon, 20 Jul 2026 17:53:00 -0400

si-local-file:///var/storage/secattach/20260720/26790615.html

Form SCHEDULE 13G/A Phathom Pharmaceuticals, Filed by: MILLENNIUM MANAGEMENT LLC

Mon, 20 Jul 2026 17:53:00 -0400

si-local-file:///var/storage/secattach/20260720/26790615.html

Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026

Mon, 20 Jul 2026 08:00:00 -0400

Management to host conference call on Thursday, July 30, 2026, at 8:00 am EDT

FLORHAM PARK, N.J., July 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today announced that it will host a live webcast at 8:00 am EDT on Thursday, July 30, 2026, to report its second quarter 2026 financial results and provide a business update.

A live webcast and additional information about the presentation can be accessed on the Events & Presentations section of the Phathom website at

Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026

Mon, 20 Jul 2026 08:00:00 -0400

Management to host conference call on Thursday, July 30, 2026, at 8:00 am EDT

A live webcast and additional information about the presentation can be accessed on the Events & Presentations section of the Phathom website at

Form 4 Phathom Pharmaceuticals, For: Jul 14 Filed by: Breedlove Robert Charles

Thu, 16 Jul 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260716/26780073.html

Form 4 Phathom Pharmaceuticals, For: Jul 14 Filed by: Breedlove Robert Charles

Thu, 16 Jul 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260716/26780073.html

Form 8-K Phathom Pharmaceuticals, For: Jun 23

Tue, 23 Jun 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260623/26676124.html

Form 8-K Phathom Pharmaceuticals, For: Jun 23

Tue, 23 Jun 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260623/26676124.html

Phathom completes enrollment in Phase 2 EoE trial of Voquezna

Tue, 23 Jun 2026 07:59:13 -0400

Phathom Pharmaceuticals (Nasdaq: PHAT) announced it has completed patient enrollment in its Phase 2 pHalcon-EoE-201 clinical trial, which is evaluating VOQUEZNA (vonoprazan) tablets as an investigational treatment for eosinophilic esophagitis (EoE) in adults. The company said enrollment was completed ahead of schedule.

The study enrolled 95 adults with endoscopically confirmed EoE and dysphagia across 41 U.S. sites. Participants were randomized evenly to receive either VOQUEZNA 20 mg or placebo once daily for 12 weeks in the double-blind portion of the trial. Patients completing that phase may enter a 12-week open-label extension in which all participants receive VOQUEZNA 20 mg once daily.

Topline